Genocea Biosciences Inc. (NASDAQ:GNCA) – Equities research analysts at FBR & Co lowered their FY2020 earnings estimates for shares of Genocea Biosciences in a research report issued to clients and investors on Friday, according to Zacks Investment Research. FBR & Co analyst C. James now anticipates that the brokerage will post earnings of $2.06 per share for the year, down from their prior forecast of $2.09. FBR & Co has a “Buy” rating and a $17.00 price target on the stock.

Genocea Biosciences (NASDAQ:GNCA) last issued its quarterly earnings data on Thursday, August 4th. The company reported ($0.39) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.44) by $0.05. Genocea Biosciences had a negative net margin of 5,121.17% and a negative return on equity of 47.87%.

Several other equities analysts also recently issued reports on the stock. Piper Jaffray Cos. reduced their price target on shares of Genocea Biosciences from $9.00 to $12.00 and set an “overweight” rating for the company in a report on Thursday, September 29th. Needham & Company LLC reissued a “buy” rating and set a $15.00 price target on shares of Genocea Biosciences in a report on Thursday, September 29th. Finally, Zacks Investment Research raised shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $4.75 price target for the company in a report on Tuesday, July 5th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $16.96.

Shares of Genocea Biosciences (NASDAQ:GNCA) traded down 0.45% during midday trading on Monday, reaching $4.44. 251,286 shares of the company were exchanged. The company’s market capitalization is $125.80 million. Genocea Biosciences has a 52-week low of $2.56 and a 52-week high of $8.20. The firm’s 50 day moving average is $5.35 and its 200-day moving average is $4.73.

A number of large investors have recently modified their holdings of GNCA. Franklin Resources Inc. boosted its stake in shares of Genocea Biosciences by 37.0% in the first quarter. Franklin Resources Inc. now owns 2,886,600 shares of the company’s stock valued at $22,342,000 after buying an additional 779,400 shares during the period. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Genocea Biosciences during the first quarter valued at approximately $662,000. Paloma Partners Management Co acquired a new stake in shares of Genocea Biosciences during the second quarter valued at approximately $334,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Genocea Biosciences during the first quarter valued at approximately $565,000. Finally, Vanguard Group Inc. boosted its stake in shares of Genocea Biosciences by 9.5% in the second quarter. Vanguard Group Inc. now owns 656,515 shares of the company’s stock valued at $2,691,000 after buying an additional 57,062 shares during the period. Hedge funds and other institutional investors own 56.49% of the company’s stock.

About Genocea Biosciences

Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.

5 Day Chart for NASDAQ:GNCA

Get a free copy of the Zacks research report on Genocea Biosciences (GNCA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related stocks with our FREE daily email newsletter.